Clinical efficacy of codergocrine mesylate in children with learning difficulties.
A double-blind placebo-controlled study in children showed codergocrine mesylate to be effective in improving cognitive functions and behavioural symptoms associated with learning disorders. Forty randomly grouped children of either sex were given an increasing dosage of codergocrine mesylate and followed up for 12 weeks. A significant improvement was noted in speech (acquisition of new words, comprehensibility/meaningfulness of speech), sociability, attention/concentration, comprehension and memory. Improvement in behaviour (emotional lability and cooperativeness) was also noted. Problems of assessing cognitive progress in very young children with culturally appropriate methods were encountered.
D000293:Adolescent; D001288:Attention / Q000187:drug effects; D002648:Child; D002652:Child Behavior / Q000187:drug effects; D002986:Clinical Trials as Topic; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007859:Learning Disabilities / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D012220:Rhinitis / Q000139:chemically induced; D012919:Social Behavior; D013065:Speech Intelligibility / Q000187:drug effects
D004088:Dihydroergotoxine